Navigation Links
Neuradiab in Medical News

Bradmer provides Phase III Neuradiab trial update and guidance

TSX: BMR TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it held a pre-Phase III meeting with the U.S. Food and Drug ...

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

...equally. We continue to evaluate opportunities to maximize the value of the neuradiab asset, however a substantial portion of the existing cash on hand will be u...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2009 first quarter operational and financial results

...luate strategic options. "Despite our pride in the progress made bringing neuradiab from a single-site Phase II program to a multicenter Phase III registration...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

...tinuing to evaluate strategic options. "We have successfully transitioned neuradiab from a Phase II compound with compelling results at a single site to a cGMP...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer implements cash conservation plan

...tends to maintain the ability to pursue business development strategies for neuradiab and is continuing to explore opportunities that would permit further develo...lment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

...l patient survival from 53 to 64 weeks. About neuradiab neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference

... form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency. Bradmer Pharmaceuticals ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

...ponse of newly diagnosed GBM patients treated with neuradiab as an adjunct to the current standard of care, con...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...

Bradmer announces 2008 third quarter operational and financial results

...ART Trial and successfully dosed patients with neuradiab at multiple sites; - Announced new data from the...llow a two week extension of the shelf life of neuradiab beyond the current six-day specification; and ...y to provide a definitive answer on the benefit of neuradiab in the newly diagnosed GBM population." The Phas...

Bradmer to present at Rodman & Renshaw Healthcare Conference

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Neuradiab in Medical Technology

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

TSX: BMR TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that new research published by an independent team in Basel, Switzerland validates tenascin as ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

...ical trial, termed the GLASS-ART Trial, evaluating neuradiab as an adjunct therapy to the current standard of c...e control arm. "These PFS data from the Phase II neuradiab trials exceed the results achieved in any other cl...nt of median overall survival, the opportunity for neuradiab to demonstrate a patient benefit via the parameter...
Neuradiab in Biological Technology

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy for patien...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Other Tags
(Date:5/6/2015)... Dallas, TX (PRWEB) May 06, 2015 ... 2, Issue 1 of Patient Experience Journal (PXJ), ... and proven practices around understanding and improving patient experience. ... elevating the patient experience conversation globally, helps align the ... and impact. , Published in association with The ...
(Date:5/6/2015)... Marketing Maven announces a ... sanitation and hygiene nonprofit by GuideStar’s Philanthropedia. , “WaterAid ... and it brings our agency great joy to work ... “The ongoing relationship between WaterAid and Marketing ... learn about and support the nonprofit as they aim ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Wolters ... healthcare professionals and students, announced today that in a ... confirmed that use of the clinical decision support resource ... the end of 2014, UpToDate users in more than ... topics per month, on average. In Germany alone, 95% ...
(Date:5/6/2015)... 06, 2015 TU-Automotive has opened press ... autonomous vehicles make it to the headlines of major ... Nissan, GM, Volvo and Hyundai ready to share their ... is the only way for press to go behind ... Wright, marketing director, TU-Automotive said “This year we’re releasing ...
(Date:5/6/2015)... GA (PRWEB) May 06, 2015 ... chosen Hexagon Geospatial technology to manage and distribute imagery, ... Australia is one of the driest continents on earth, ... through times of drought and erratic seasonal rainfalls has ... supply solutions. , Water NSW manages raw water supplies ...
Breaking Medicine News(10 mins):Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Press Registration for TU-Automotive Detroit Now Open 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
Other Contents